podcast about glp 1 The Holistic GLP-1 with Elizabeth McGann S6.E8: My Life on GLP1:

Curious about GLP-1 in San Antonio

By 2030, the global prevalence of obesity is expected to reach one billion

After facing challenges with access and weight regain, Chuck joined Ro to share his story, spark real conversations about GLP-1s, and help others feel confident taking control of their health

The patient must: Be age 18 or older Have eligible Medicare Part D coverage Be prescribed treatment specifically for weight reduction and maintenance Participate in ongoing nutrition and physical activity intervention Not have already received a GLP-1 through their Part D plan Not be seeking coverage for another Part D-coverable indication, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, MASH, or cardiovascular risk reduction The patient must also have met one of these criteria when GLP-1 therapy was originally started: BMI 35 BMI 30 plus HFpEF, uncontrolled hypertension despite 2 medications, or CKD stage 3a+ BMI 27 plus prediabetes, prior MI, prior stroke, or symptomatic peripheral artery disease Important: Eligibility is based on BMI at treatment initiation, not necessarily the patients current BMI

Now Pfizers public declaration that its at the end of the beginning in entering the GLP1 market marks a pivotal

Those switched to placebo then regained 14.0% over the next 52 weeks, while those who continued tirzepatide lost an additional 5.5%